Entering text into the input field will update the search result below

Denali presents positive results from early-stage studies of BIIB122/DNL151 in Parkinson’s disease

  • Denali Therapeutics (NASDAQ:DNLI) announces final results from Phase 1 and 1b studies of its small molecule LRRK2 inhibitor, BIIB122/DNL151, which is being developed in collaboration with Biogen (NASDAQ:BIIB) as a potential treatment of Parkinson’s disease.
  • Safety and biomarker goals were

Recommended For You

About DNLI Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
DNLI--
Denali Therapeutics Inc.